Hao Li

Hao Li


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in ACS Chemical Biology
Verified
Journal Article
Closed access
YCYulin Cong
Yulin Cong
KLKun Liu
Kun Liu
ZHZihong Huang
Zihong Huang
JLJunjun Lu
Junjun Lu
HWHONGHUI WANG
HONGHUI WANG
HLHao Li
Hao Li

2 June 2023 in Heliyon
Verified
Journal Article
Open access
WZWeijia Zhang
Weijia Zhang
LOLing Ou
Ling Ou
CPChang Peng
Chang Peng
SSShuyi Sang
Shuyi Sang
ZFZhong Feng
Zhong Feng
MYMeicun Yao
Meicun Yao
Sanguisorba officinalis L., a traditional Chinese medicine (TCM) called DiYu (DY) in China, has a strong tradition of utilization as a scorching, blood-cooling, and hemostatic medication, and was used for cancer prevention and treatment due to its potential immune-enhancing and hematological toxicity-reducing effects. Previous studies have reported significant effects of DY on cancers including colorectal cancer (CRC), which is one of the most common malignancies worldwide. The first-line cure 5-fluorouracil (5-FU) plays decisive commerce in the sedative of CRC as a clinically available chemotherapeutic agent. One of the primary causes of cancer treatment failure is the acquisition of chemotherapy drug resistance. In order to successfully combat the emergence of chemoresistance, it is essential to identify herbs or traditional Chinese medicine that have adjuvant therapeutic effects on CRC. Therefore, this study aimed to determine whether DY could improve the sensitivity, conquer the chemoresistance of 5-FU-resistant CRC cells, and investigate its intrinsic mechanism. MTT, Hoechst 33258 staining, and flow cytometry assays were used to determine the anticancer activity of DY alone or in combination with 5-FU against 5-FU-resistant CRC cells (RKO-R and HCT15-R) and wound healing assays were conducted to detect cell migration. Transcriptomic techniques were carried out to explore the effect and mechanism of DY on drug-resistant CRC cells. Western Blot and RT q-PCR assays were performed to validate the mechanism by which DY overcomes drug-resistant CRC cells. These results indicated that DY alone or in combination with 5-FU significantly inhibited the proliferation and the migration of resistant CRC cells, and potentiated the susceptibility of 5-FU to drug-resistant CRC cells. GO and KEGG enrichment analysis showed that the mechanisms of drug resistance in CRC cells and DY against drug-resistant CRC cells highly overlapped, involved in the modulation of biological processes such as cell migration, positive regulation of protein binding and cytoskeleton, and MAPK (Ras-ERK-MEK), PI3K/Akt, and other signaling pathways. Moreover, DY can mediate the expression of p-R-Ras, p-ERK1/2, p-MEK1/2, p-PI3K, p-AKT, HIF-1A and VEGFA proteins. In addition, DY significantly suppressed the expression of AKT3, NEDD9, BMI-1, and CXCL1 genes in resistant CRC cells. In conclusion, DY could inhibit the proliferation and migration of 5-FU-resistant cells and strengthen the sensitivity of 5-FU to CRC-resistant cells. Furthermore, DY may prevail over chemoresistance through the Ras/MEK/ERK and PI3K/Akt pathways. These findings imply that DY may be a potential drug for clinical treatment or adjuvant treatment of drug-resistant CRC.

7 March 2025 in Chinese Chemical Letters
Verified
Journal Article
Closed access
KLKun Liu
Kun Liu
JLJunjun Lu
Junjun Lu
JLJincheng Lin
Jincheng Lin
YCYulin Cong
Yulin Cong
XLXiongfeng Luo
Xiongfeng Luo
HLHao Li
Hao Li

3 May 2016 in Scientific Reports
Verified
Journal Article
Open access
HLHao Li
Hao Li
YHYue Huang
Yue Huang
YYYUE YU
YUE YU
TLTianqi Li
Tianqi Li
GLGenxi Li
Genxi Li
JAJun-Ichi Anzai
Jun-Ichi Anzai
Diseases such as cancer arise from systematical reconfiguration of interactions of exceedingly large numbers of proteins in cell signaling. The study of such complicated molecular mechanisms requires multiplexed detection of the inter-connected activities of several proteins in a disease-associated context. However, the existing methods are generally not well-equipped for this kind of application. Here a method for analyzing functionally linked protein activities is developed based on enzyme controlled pairing between complementary peptide helix strands, which simultaneously enables elaborate regulation of catalytic activity of the paired peptides. This method has been used to detect three different types of protein modification enzymes that participate in the modification of extracellular matrix and the formation of invasion front in tumour. In detecting breast cancer tissue samples using this method, up-regulated activity can be observed for two of the assessed enzymes, while the third enzyme is found to have a subtle fluctuation of activity. These results may point to the application of this method in evaluating prometastatic activities of proteins in tumour.

12 June 2026 in Hepatology Communications
Verified
Journal Article
Open access
YLYue Luo
Yue Luo
YZYuefeng Zhang
Yuefeng Zhang
QZQian Zhang
Qian Zhang
XLXiaohan Li
Xiaohan Li
KCKaiwei Cai
Kaiwei Cai
ZXZhiyong Xie
Zhiyong Xie
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) has become a global health challenge for which there are currently no approved drugs. Indole-3-propionic acid (IPA), as one of the primary metabolites of gut microbiota, can influence the development of liver diseases through the gut-liver axis, but how it contributes to liver diseases remains unclear. The present study was conducted to explore the possible molecular mechanisms of IPA in the development of MASLD. Methods: Metabolomic analysis compared serum and fecal metabolite profiles between MASLD and normal mice. The effects of microbial metabolite IPA on MASLD were evaluated through the utilization of a mouse model and cell models. Transcriptome data analysis was used, and further validation was conducted through flow cytometry, western blotting, RNA interference, and immunoprecipitation. Results: Serum and fecal IPA levels in high-fat diet–fed mice were significantly decreased compared with those of normal chow diet–fed mice. IPA supplementation reduced hepatic lipid accumulation and alleviated insulin resistance, liver damage, and steatosis development in high-fat diet–fed mice, while gut microbiota dysbiosis was restored. Mechanistic analysis suggested that IPA promoted FMO2 expression, enhancing the interaction between FMO2 and protein kinase R–like endoplasmic reticulum kinase (PERK) and inhibiting the PERK/eIF2α/ATF4/CHOP signaling cascade, then mitigating endoplasmic reticulum (ER) stress, such as reducing hepatocyte apoptosis and reactive oxygen species levels, ultimately improving MASLD. Conclusions: IPA can promote the expression of FMO2, which binds to PERK within the ER of hepatocytes. This binding process inhibits the phosphorylation of PERK, thereby affecting PERK-mediated ER stress, and subsequently leading to a reduction in hepatocyte apoptosis and oxidation. This study puts forward the IPA/FMO2/PERK axis as a potential therapeutic target in ER stress for MASLD.

28 March 2024 in Chinese Chemical Letters
Verified
Journal Article
Closed access
KLKun Liu
Kun Liu
YCYulin Cong
Yulin Cong
XLXiongfeng Luo
Xiongfeng Luo
MYMeicun Yao
Meicun Yao
ZXZhiyong Xie
Zhiyong Xie
HLHao Li
Hao Li